AstraZeneca Will Acquire RSV Vaccine Developer Icosavax For $1.1 Billion

The acquisition means AstraZeneca will gain access to Icosavax ’s experimental vaccine which targets both RSV and hMPV.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: Business /business Innovation /innovation Healthcare /healthcare Breaking breaking-news topline Source Type: news